16
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Identification of mouse CD4 + T cell epitopes in SARS-CoV-2 BA.1 spike and nucleocapsid for use in peptide:MHCII tetramers

      Preprint
      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Understanding adaptive immunity against SARS-CoV-2 is a major requisite for the development of effective vaccines and treatments for COVID-19. CD4 + T cells play an integral role in this process primarily by generating antiviral cytokines and providing help to antibody-producing B cells. To empower detailed studies of SARS-CoV-2-specific CD4 + T cell responses in mouse models, we comprehensively mapped I-A b-restricted epitopes for the spike and nucleocapsid proteins of the BA.1 variant of concern via IFNγ ELISpot assay. This was followed by the generation of corresponding peptide:MHCII tetramer reagents to directly stain epitope-specific T cells. Using this rigorous validation strategy, we identified 6 reliably immunogenic epitopes in spike and 3 in nucleocapsid, all of which are conserved in the ancestral Wuhan strain. We also validated a previously identified epitope from Wuhan that is absent in BA.1. These epitopes and tetramers will be invaluable tools for SARS-CoV-2 antigen-specific CD4 + T cell studies in mice.

          Related collections

          Most cited references25

          • Record: found
          • Abstract: found
          • Article: not found

          Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals

          Summary Understanding adaptive immunity to SARS-CoV-2 is important for vaccine development, interpreting coronavirus disease 2019 (COVID-19) pathogenesis, and calibration of pandemic control measures. Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2−specific CD8+ and CD4+ T cells were identified in ∼70% and 100% of COVID-19 convalescent patients, respectively. CD4+ T cell responses to spike, the main target of most vaccine efforts, were robust and correlated with the magnitude of the anti-SARS-CoV-2 IgG and IgA titers. The M, spike and N proteins each accounted for 11-27% of the total CD4+ response, with additional responses commonly targeting nsp3, nsp4, ORF3a and ORF8, among others. For CD8+ T cells, spike and M were recognized, with at least eight SARS-CoV-2 ORFs targeted. Importantly, we detected SARS-CoV-2−reactive CD4+ T cells in ∼40-60% of unexposed individuals, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS-CoV-2.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Lethal infection of K18-hACE2 mice infected with severe acute respiratory syndrome coronavirus.

            The severe acute respiratory syndrome (SARS), caused by a novel coronavirus (SARS-CoV), resulted in substantial morbidity, mortality, and economic losses during the 2003 epidemic. While SARS-CoV infection has not recurred to a significant extent since 2003, it still remains a potential threat. Understanding of SARS and development of therapeutic approaches have been hampered by the absence of an animal model that mimics the human disease and is reproducible. Here we show that transgenic mice that express the SARS-CoV receptor (human angiotensin-converting enzyme 2 [hACE2]) in airway and other epithelia develop a rapidly lethal infection after intranasal inoculation with a human strain of the virus. Infection begins in airway epithelia, with subsequent alveolar involvement and extrapulmonary virus spread to the brain. Infection results in macrophage and lymphocyte infiltration in the lungs and upregulation of proinflammatory cytokines and chemokines in both the lung and the brain. This model of lethal infection with SARS-CoV should be useful for studies of pathogenesis and for the development of antiviral therapies.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Structure-based design of prefusion-stabilized SARS-CoV-2 spikes

              The COVID-19 pandemic has led to accelerated efforts to develop therapeutics and vaccines. A key target of these efforts is the spike (S) protein, which is metastable and difficult to produce recombinantly. Here, we characterized 100 structure-guided spike designs and identified 26 individual substitutions that increased protein yields and stability. Testing combinations of beneficial substitutions resulted in the identification of HexaPro, a variant with six beneficial proline substitutions exhibiting ~10-fold higher expression than its parental construct and the ability to withstand heat stress, storage at room temperature, and three freeze-thaw cycles. A 3.2 Å-resolution cryo-EM structure of HexaPro confirmed that it retains the prefusion spike conformation. High-yield production of a stabilized prefusion spike protein will accelerate the development of vaccines and serological diagnostics for SARS-CoV-2.
                Bookmark

                Author and article information

                Journal
                bioRxiv
                BIORXIV
                bioRxiv
                Cold Spring Harbor Laboratory
                17 November 2023
                : 2023.11.16.566918
                Affiliations
                [1 ]Center for Immunology and Inflammatory Diseases, Massachusetts General Hospital, Boston, MA, United States
                [2 ]Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA, United States
                [3 ]Harvard Medical School, Boston, MA, United States
                [4 ]Center for Vaccine Innovation, La Jolla Institute for Immunology, La Jolla, CA, United States
                [5 ]Endocrine Division, Massachusetts General Hospital, Boston, MA, United States
                [6 ]Ragon Institute of MGH, MIT, and Harvard, Cambridge, MA, United States
                [7 ]Program in Health Sciences and Technology, Harvard Medical School and Massachusetts Institute of Technology, Boston, MA, United States
                [8 ]Division of Gastroenterology, Massachusetts General Hospital, Boston, MA, United States
                [9 ]Department of Medicine, University of California San Diego, La Jolla, CA, United States
                [10 ]Division of Pulmonary and Critical Care Medicine, Massachusetts General Hospital, Boston, MA, United States
                Author notes
                [* ]Corresponding author: James J. Moon, jjmoon@ 123456mgh.harvard.edu
                [†]

                First authorship

                [‡]

                Senior authorship

                [@]

                present address: Universidad Cardenal Herrera-CEU, CEU Universities, 46113 Valencia, Spain

                Author contributions

                LBM, JBA, AL, and JM conceived the study. LBM, JBA, JN, and TN performed the majority of the experiments. JN, KM, SLB, CH, JM, and EOS generated recombinant proteins. AN, MG, AG, AK, and GG generated peptide libraries. LBM, JBA, AL, and JM designed the experiments and analyzed the data. JBA and JM wrote the manuscript. All authors reviewed and approved the final manuscript.

                Author information
                http://orcid.org/0000-0001-8246-931X
                Article
                10.1101/2023.11.16.566918
                10680761
                38014059
                e605353f-07e6-4e42-8926-544358fbc211

                This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which allows reusers to copy and distribute the material in any medium or format in unadapted form only, for noncommercial purposes only, and only so long as attribution is given to the creator.

                History
                Funding
                Funded by: National Institutes of Health, AL, EOS, JM, GG, Massachusetts Consortium on Pathogen Readiness, GG, JM, Massachusetts General Hospital Executive Committee on Research, GG, AL, JM, Bill and Melinda Gates Foundation, GG, Burroughs Wellcome Fund, GG
                Award ID: P01 AI165072, DP2AI154421, R01AI176533, DP1DA058476
                Categories
                Article

                Comments

                Comment on this article